Hsp90 Rabbit pAb
- Known as:
- Hsp90 Rabbit pAb
- Catalog number:
- ASASPA-836F
- Product Quantity:
- 200 µg
- Category:
- -
- Supplier:
- Other suppliers
- Gene target:
- Hsp90 Rabbit pAb
Related genes to: Hsp90 Rabbit pAb
- Gene:
- HSP90AA1 NIH gene
- Name:
- heat shock protein 90 alpha family class A member 1
- Previous symbol:
- HSPC1, HSPCA
- Synonyms:
- Hsp89, Hsp90, FLJ31884, HSP90N
- Chromosome:
- 14q32.31
- Locus Type:
- gene with protein product
- Date approved:
- 1990-06-27
- Date modifiied:
- 2016-10-11
Related products to: Hsp90 Rabbit pAb
guanine nucleotide binding protein alpha inhibiting activity polypeptide 1 (GNAI1) polyclonal antibody kinase suppressor of ras (KSR) polyclonal antibody(Alpha)_ 1 _ antitrypsin (A1AT) POLYCLONAL Rabbit anti_human(Alpha)_ Feto Protein (AFP) POLYCLONAL Rabbit anti_human(Alpha)_ Feto Protein (AFP) POLYCLONAL Rabbit anti_human(Alpha)_1_ antitrypsin (A1AT) POLYCLONAL Rabbit anti_human(Arg6,b_cyclohexyl_Ala8,D_Tic16,Arg17,Cys18)_Atrial Natriuretic Factor (6_18) amide (mouse, rabbit, rat) Salt _ Binding (Disulfide_bond) Synonym A71915 SumFormula C69H116N26O15S2(Arg6,b_cyclohexyl_Ala8,D_Tic16,Arg17,Cys18)_Atrial Natriuretic Factor (6_18) amide (mouse, rabbit, rat) Salt _ Binding (Disulfide_bond) Synonym A71915 SumFormula C69H116N26O15S2(Arg6,β-cyclohexyl-Ala8,D-Tic16,Arg17,Cys18)-Atrial Natriuretic Factor (6-18) amide (mouse, rabbit, rat)
A71915 98% C69H116N26O15S2 CAS:(Arg8)-Vasopressin - Diluted Antiserum for RIA, Host Rabbit(Arg8)-Vasopressin - Diluted Antiserum for RIA, Host: Rabbit(Arg8)-Vasopressin - Diluted Antiserum for RIA, Host: Rabbit(Arg8)-Vasopressin - EIA Kit (H - sr, pl), Host Rabbit, Extraction-free, CE-marked(Arg8)-Vasopressin - EIA Kit (H - sr, pl), Host RabbitExtraction-freeCE-marked(Arg8)-Vasopressin - EIA Kit (H - sr, pl), Host: Rabbit, Extraction-free, CE-marked Related articles to: Hsp90 Rabbit pAb
- Fraxinus mandshurica (Oleaceae, Fraxinus) seeds serve as food and condiments in traditional American and European diets. This study provides the first systematic evaluation of the therapeutic effects of F. mandshurica seed extract on T2DM. This study evaluated the effects of F. mandshurica seed extract on glucose-lipid metabolism, hepatorenal function, and gut microbiota in an HFD/STZ-induced T2DM mouse model. Through UPLC-Q-TOF-MS chemical characterization and phytochemical analysis, combined with network pharmacology and molecular docking techniques, potential active components and their corresponding targets were predicted. Critically, the predicted activity of 18 iridoid monomers was confirmed by evaluating their ability to enhance glucose consumption in L02 cells. F. mandshurica seed extract significantly reduced body weight, TC, TG, and blood glucose levels, improved insulin sensitivity and glucose tolerance, and alleviated hepatorenal injury. Additionally, it regulated the gut microbiota by reducing the Firmicutes/Bacteroidetes ratio. Network pharmacology analysis identified AGE-RAGE and TNF signaling as core anti-diabetic pathways. Key active components, including bisandrographolide A, ligstroside, reptoside, oleuropein, fraxoside, koaburside, and mudanpioside D, were identified and selected for molecular docking. The results indicate that these active components form stable ligand-receptor complexes with target proteins (HRAS, MAPK1, HSP90AA1, MMP9 and AKT1) via hydrogen bonds, hydrophobic interactions, π-π stacking and salt bridges. Finally, 18 iridoid glucosides from the F. mandshurica seed were shown to promote glucose consumption, with efficacy ranging from 7.27% to 71.52%. This study reveals that F. mandshurica seeds and their characteristic iridoid components possess promising prospects as candidates for developing natural anti-diabetic therapeutics. - Source: PubMed
Publication date: 2026/07/08
Zhou WeiLi HaoyuGuo QuanZhang ShanshanBai LuZhang YuWang MengjiaoBai NaishengGuo Sen - Microbial biofilm, quorum sensing (QS)-mediated virulence and oxidative stress-induced inflammation are interrelated pathological processes that play a crucial role in persistent infections and chronic illnesses. Due to the multifactorially of such processes, isolated target-based approaches to therapy usually do not provide long-term effectiveness. A combined network pharmacology and multi-level computational approach was used in order to clarify the molecular mechanisms underlying the antibiofilm, anti-quorum sensing (anti-QS), and antioxidant activities of thirty-three bioactive compounds found in the essential oils (EOs) of Citrus medica cv. Liscia and cv. Rugosa. Human potential protein targets were predicted and intersected with disease-associated genes, and 317 common targets were obtained, which were further viewed in terms of protein-protein interaction network and hub gene. The analysis of the functional enrichment demonstrated that the targets play a large role in oxidative stress response, homeostasis of inflammatory response, signal transduction, apoptosis, and membrane-related processes. Molecular docking analysis reveals strong and consistent binding affinities of aromadendrene, germacrene D, caryophyllene oxide, and carvacrol to major hub proteins such as HSP90AA1, AKT1, TNF, IL6, IL1B, and STAT3. Principal component and secondary structure analysis, and molecular dynamics simulations were used to further assess the HSP90AA1-aromadendrene complex, which was found to be among the most stable complexes. Analysis based on density functional theory was used to support good electronic properties and chemical stability of the lead compound and ADMET profiling revealed acceptable pharmacokinetics and drug-like properties. All these findings indicate a multi-target, multi-pathway therapeutic paradigm and constitute a powerful computational framework of Citrus-based agents against biofilm-associated infections and oxidative stress-related disorders. - Source: PubMed
Publication date: 2026/07/07
Noumi EmiraAlabbosh Khulood FahadAlsenani QusaiAlshammari NajahAlshammari MamdouhAdnan MohdCeylan OzgurKadri AdelSnoussi MejdiDe Feo Vincenzo - Network pharmacology and bioinformatics approaches may provide valuable insights into pharmacological effects by enabling a system-level understanding of how drugs interact with biological networks rather than single targets. The study aimed to elucidate the therapeutic mechanisms of Azadirachta indica leaf extract (AILE) in hepatotoxicity and hepato-injury (HT/HI) through the identification of pathways and molecular targets via network pharmacology. Phytochemical profiling of AILE was performed by Gas Chromatography-Mass Spectrometry (GC-MS). SMILES structures of identified phytochemicals were retrieved from PubChem, and ADMET properties were assessed. Five non-hepatotoxic compounds with high absorption were prioritized. Their potential targets and hepatotoxicity-related genes were predicted using SwissTargetPrediction and GeneCards, followed by drug-target network construction in Cytoscape. Hub genes were identified through protein-protein interaction (PPI) analysis (STRING) and enrichment studies (ShinyGO, KEGG). Gene regulatory networks were built using TRRUST and miRNet 2.0, and molecular docking was performed to evaluate target-protein binding affinities. In the results, ADMET profiling identified five candidate phytochemicals: Butane, 1,1-diethoxy-3-methyl (B), 1,1,3-triethoxybutane (T), Propane, 1,1,3-triethoxy (P), Gamma-Sitosterol (G), and Caryophyllene (C), with favorable absorption. A total of 478 potential compound targets (BTPGC) were predicted, while 1243 HT/HI-related genes were identified, of which 73 overlapped as potential therapeutic targets. PPI analysis generated a network of 73 nodes and 582 edges. GO enrichment revealed involvement in lipid response, oxidative response, programmed cell death, and apoptosis. CytoHubba highlighted six hub genes (TNF, CASP3, ESR1, MAPK3, EGFR, and HSP90AA1). TRRUST identified 15 transcription factors, while miRNet predicted four regulatory miRNAs (miR-155-5p, miR-122-5p, miR-328, and miR-16). This integrative computational network pharmacology analysis provides novel insights into the pathogenesis of liver diseases (HT/HI) and identifies potential therapeutic targets, exploring biomarkers for future experimental validation and clinical translation. - Source: PubMed
Publication date: 2026/07/07
Kumari MrinaliniSrivastava AtulSubhashini Sharma ShaliniSah Shyam BabuSanjeev Kumar - Type 2 diabetes mellitus (T2DM) and sarcopenia demonstrate a significant comorbidity, particularly in the elderly, yet the molecular mechanisms linking them, especially through oxidative stress, remain incompletely understood. This study aimed to identify oxidative stress-related hub genes involved in T2DM-associated sarcopenia (T2DS) by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data with machine learning. We analyzed scRNA-seq datasets (GSE244515, GSE268953) to characterize cellular heterogeneity and bulk RNA-seq datasets (GSE202295, GSE226151) for differential expression. Cell type annotation revealed key involvement of neuromuscular junctions and myofibers. Functional enrichment analyses highlighted pathways like the proteasome, TNF signaling, and ubiquitin-mediated proteolysis. From an initial set of oxidative stress-related genes, a comprehensive machine learning framework comprising 127 algorithm combinations was employed. The Lasso+Stepglm[both] model identified 12 candidate genes. Subsequent Protein-Protein Interaction (PPI) network analysis refined this to seven core hub genes: TNFRSF1B, PSMA2, UBE2D1, UBE2N, HSP90AA1, RAD23A, and DNAJB1. These genes are functionally interconnected, primarily implicating TNFRSF1B-mediated inflammatory signaling that activates the ubiquitin-proteasome system, leading to enhanced protein degradation-a key pathway in muscle atrophy. ROC curve analysis confirmed the strong diagnostic value of these hub genes across training, test, and external validation sets. Our findings systematically reveal novel oxidative stress-related hub genes and mechanisms in T2DS, providing potential biomarkers and therapeutic targets for this debilitating condition. - Source: PubMed
Publication date: 2026/07/07
Zhu GuangwenZou KaiLiang YiXie LitingChen Qiu - Hepatocellular carcinoma (HCC) is a prevalent malignancy with globally increasing incidence and mortality rates. The identification of a robust prognostic signature remains an unmet clinical need in HCC treatment. In this study, transcriptome and clinical data of HCC patients were retrieved from The Cancer Genome Atlas (TCGA) database, and the top 100 HIF-1α pathway-related genes (HPRGs) were selected from GeneCards. Using univariate Cox regression, LASSO-regularized Cox regression, and multivariate Cox regression, a four-gene prognostic signature (HSP90AA1, ANGPT2, NPM1 and LDHA) was established. Its robust predictive performance was validated using receiver operating characteristic (ROC) curve analysis, the concordance index (C-index), and decision curve analysis (DCA). Subsequently, HCC patients were stratified into high- and low-risk groups according to the median risk score, and survival analysis confirmed markedly inferior prognosis for patients in the high-risk group. Furthermore, the expression level of the signature genes correlated positively with risk score and were overexpressed in high-risk HCC tissues in the GSE121248 and GSE14520 datasets. Besides, the drug sensitivity analysis demonstrated that the high-risk group exhibited greater sensitivity to 5-fluorouracil, gemcitabine, paclitaxel, sorafenib, and sunitinib. Mendelian randomization (MR) and Bayesian colocalization analyses validated HSP90AA1 and LDHA as potential druggable targets. Furthermore, functional validation experiments demonstrated that knockdown of HSP90AA1 could impede the proliferation, migration, and invasion of HCC cells. Overall, this research presents a novel prognostic signature for HCC and highlights the potential of HSP90AA1 as a biomarker and therapeutic target. - Source: PubMed
Publication date: 2026/07/06
Zhang YanyanHuang HantaoSu QiminZhou YanLi XinyanPeng KunweiZhan Qi